Literature DB >> 21441120

Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?

Kathryn A Seely1, Paul L Prather, Laura P James, Jeffery H Moran.   

Abstract

The principal psychoactive component of marijuana, Δ(9)-tetrahydrocannabinol (THC), activates CB1 cannabinoid receptors (CB1Rs). Unfortunately, pharmacological research into the design of effective THC analogs has been hampered by psychiatric side effects. THC-based drug design of a less academic nature, however, has led to the marketing of "synthetic marijuana," labeled as K2 or "Spice," among other terms, which elicits psychotropic actions via CB1R activation. Because of structural dissimilarity to THC, the active ingredients of K2/Spice preparations are widely unregulated. The K2/Spice "phenomenon" provides a context for considering whether marijuana-based drugs will truly provide innovative therapeutics or merely perpetuate drug abuse.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21441120      PMCID： PMC3139381          DOI： 10.1124/mi.11.1.6

Source DB:  PubMed          Journal:  Mol Interv        ISSN： 1534-0384


  118 in total

Review 1.  The endocannabinoid system: a general view and latest additions.

Authors:  Luciano De Petrocellis; Maria Grazia Cascio; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

2.  Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase.

Authors:  Pattipati S Naidu; Steven G Kinsey; Tai L Guo; Benjamin F Cravatt; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2010-04-07       Impact factor: 4.030

Review 3.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

4.  Prevalence of overweight and obesity in the United States, 1999-2004.

Authors:  Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal
Journal:  JAMA       Date:  2006-04-05       Impact factor: 56.272

5.  Pharmacology and stereoselectivity of structurally novel cannabinoids in mice.

Authors:  P J Little; D R Compton; M R Johnson; L S Melvin; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1988-12       Impact factor: 4.030

6.  Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.

Authors:  D R Compton; K C Rice; B R De Costa; R K Razdan; L S Melvin; M R Johnson; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1993-04       Impact factor: 4.030

Review 7.  Endocannabinoid system in food intake and metabolic regulation.

Authors:  David Jesudason; Gary Wittert
Journal:  Curr Opin Lipidol       Date:  2008-08       Impact factor: 4.776

8.  Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents.

Authors:  D R Compton; M R Johnson; L S Melvin; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1992-01       Impact factor: 4.030

Review 9.  Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.

Authors:  David R Janero; Alexandros Makriyannis
Journal:  Expert Opin Emerg Drugs       Date:  2009-03       Impact factor: 4.191

10.  SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes.

Authors:  Julio Rosenstock; Priscilla Hollander; Soazig Chevalier; Ali Iranmanesh
Journal:  Diabetes Care       Date:  2008-08-04       Impact factor: 17.152
View more
  35 in total

1.  Convulsions associated with the use of a synthetic cannabinoid product.

Authors:  Aaron B Schneir; Todd Baumbacher
Journal:  J Med Toxicol       Date:  2012-03

2.  Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.

Authors:  Lisa K Brents; Anna Gallus-Zawada; Anna Radominska-Pandya; Tamara Vasiljevik; Thomas E Prisinzano; William E Fantegrossi; Jeffery H Moran; Paul L Prather
Journal:  Biochem Pharmacol       Date:  2012-01-18       Impact factor: 5.858

Review 3.  Synthetic cannabinoids 2015: An update for pediatricians in clinical practice.

Authors:  Daniel Castellanos; Leonard M Gralnik
Journal:  World J Clin Pediatr       Date:  2016-02-08

Review 4.  Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids.

Authors:  Kathryn A Seely; Jeff Lapoint; Jeffery H Moran; Liana Fattore
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-04-26       Impact factor: 5.067

Review 5.  "Herbal incense": designer drug blends as cannabimimetics and their assessment by drug discrimination and other in vivo bioassays.

Authors:  Torbjörn U C Järbe; Roger S Gifford
Journal:  Life Sci       Date:  2013-07-25       Impact factor: 5.037

6.  "K2/Spice": have you updated your differentials? A case report.

Authors:  Roopa Sethi; Neha Thapa; Ashwini Saxena; Ritu Chahil
Journal:  Prim Care Companion CNS Disord       Date:  2013

7.  Supporting public health laboratory systems research.

Authors:  Burton W Wilcke; Sadira Y Del Rio Daher; Karen J Breckenridge
Journal:  Public Health Rep       Date:  2013 Sep-Oct       Impact factor: 2.792

Review 8.  Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?

Authors:  William E Fantegrossi; Jeffery H Moran; Anna Radominska-Pandya; Paul L Prather
Journal:  Life Sci       Date:  2013-09-29       Impact factor: 5.037

9.  Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.

Authors:  Maheswari Rajasekaran; Lisa K Brents; Lirit N Franks; Jeffery H Moran; Paul L Prather
Journal:  Toxicol Appl Pharmacol       Date:  2013-03-26       Impact factor: 4.219

10.  Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.

Authors:  Krishna C Chimalakonda; Kathryn A Seely; Stacie M Bratton; Lisa K Brents; Cindy L Moran; Gregory W Endres; Laura P James; Paul F Hollenberg; Paul L Prather; Anna Radominska-Pandya; Jeffery H Moran
Journal:  Drug Metab Dispos       Date:  2012-08-17       Impact factor: 3.922
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.